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Objectives: Outcomes of pediatric-onset portal hypertension are poorly defined. 
We aimed assess population-based long-term outcomes of pediatric-onset portal 
hypertension complicated by varices. 
Methods: All children with esophageal varices (n=126) were identified from 
14144 single nationwide referral center endoscopy reports during 1987-2013, 
and followed up through national health care and death registers. A 
questionnaire was sent to survivors (n=94) of whom 65 (69%) responded. 
Results: Nineteen underlying disorders included biliary atresia (35%), 
extrahepatic portal vein obstruction (35%), autosomal recessive polycystic kidney 
disease (7%), and other disorders (23%). During median follow-up of 15.2 (range 
0.5-43.1) years patients underwent median 9 (1-74) upper gastrointestinal 
endoscopies. Esophageal varices were first observed at median age 4.0 (0.3-
18.2) years, 112 (89%) patients underwent median 6 (1-56) 
sclerotherapy/banding sessions, and 61 (48%) experienced median 2 (range 1-
20) variceal bleeding episodes. Forty-eight surgical shunt procedures were 
performed to 41 (36%) patients and 38% underwent liver transplantation. Portal 
hypertensive biliopathy was diagnosed in 4 patients. Hepatopulmonary syndrome 
necessitated liver transplantation in 2 patients, hepatic encephalopathy in 2 and 
hepatorenal syndrome in 1. No patient died of variceal bleeding. Patient reported 
perception of health on a scale of 1-10 was 9 (range 4-10), and 86% reported no 
current symptoms attributable to esophageal varices. 
Conclusions: Pediatric-onset portal hypertension is a heterogeneous disease 
with significant long-term morbidity, requiring multimodal approach with 




considerable resources and continuation of follow-up in adulthood. Although 
mortality to variceal bleeding was avoided, bleeding episodes recurred also in 
adulthood, while patient reported health of long-term survivors was encouraging. 
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What is Known 
• The management of pediatric onset portal hypertension has significantly 
evolved during the last decades. 
• Management depends on the underlying liver disease. 
• Outcomes of pediatric-onset portal hypertension are poorly defined. 
 
What is New 
• Pediatric-onset portal hypertension is a heterogeneous disease with significant 
long-term morbidity. 
• With multimodal approach mortality to variceal bleeding was avoided. 
• Mortality was related to other complications of advanced liver disease and 
its treatment rather than variceal bleeding. 
• Bleeding episodes recurred also in adulthood, although patient reported health 
of long-term survivors was good. 
 
 




Abbreviations: ARPKD, Autosomal Recessive Polycystic Kidney Disease; BA, 
Biliary Atresia; EHPVO, Extrahepatic Portal Vein Obstruction; LT, Liver 
















In portal hypertension (PH) the pressure gradient between portal and venous 
systems increases over the physiological threshold (10 mmHg), resulting in abnormal 
portosystemic venous communications to decompress the portal venous system. The 
increase in the portal venous pressure results from increased blood flow resistance 
or obstruction either at a prehepatic, intrahepatic (parenchymal) or posthepatic level, 
or as their combination. In addition to gastroesophageal varices, other common 
complications of PH include splenomegaly and hypersplenism (1,2). Less common, 
but well-defined complications associated with PH, include portal hypertensive 
biliopathy, hepato-pulmonary syndrome, portopulmonary hypertension, hepatorenal 
syndrome and hepatic encephalopathy (3-9). Management and outcomes of pediatric 
PH depend on the underlying liver disease, and may include repeated surveillance 
endoscopies with primary prophylaxis as well as different surgical shunt procedures, 
which may have a significant effect on health outcomes (1,2,10-13). 
 Extrahepatic portal vein obstruction (EHPVO) is the most common prehepatic 
cause for PH in children (9). Numerous diseases of the liver parenchyma and bile 
ducts may lead to cirrhosis and PH (13). In biliary atresia (BA), despite successful 
Kasai portoenterostomy, liver fibrosis progresses rapidly leading to complicated PH 
in most (14,15). Other typical intrahepatic conditions in children include congenital 
hepatic fibrosis with or without autosomal recessive polycystic kidney disease 
(ARPKD), autoimmune liver diseases, and other conditions leading to cirrhosis. 
Posthepatic causes of PH, such Budd-Chiari syndrome, are rare in children (12,16). 
 The management of pediatric PH has significantly evolved during the last 
decades (1). Mesoportal bypass or Rex shunt was introduced in 1992 by de Ville de 
Goyet et al and is now considered the surgical treatment of choice for EHPVO. The 




procedure restores physiologic portal venous blood flow and may be considered 
even pre-emptively when anatomical limitations are not encountered (17-22). Results 
of Kasai portoenterostomy for BA and liver transplantations (LT) have also improved 
as management protocols have evolved (14,23,24). The role of endoscopic variceal 
surveillance with primary prophylaxis using sclerotherapy or band ligation remains 
debatable and is variably performed in different centers (10-12,22,25-29).  
 Only few reports are available on long-term outcomes of pediatric-onset PH 
and these studies typically focus on one specific disease with relatively short follow-
up times (15,20,30-32). Comparative long-term data extending to adulthood on 
management and outcomes are few. In the present single center registry-based 
national follow-up study, we analyzed long-term outcomes and patient reported 
health perceptions of pediatric onset PH complicated by varices. 
 
METHODS 
Study population and design 
In total, 14 144 consecutive upper gastrointestinal endoscopy reports from 1987-
2013 were reviewed to identify all consecutive patients treated for PH 
complicated by gastroesophageal varices in the Helsinki University Children’s 
Hospital (See Supplemental Figure 1, Supplemental Digital Content 1, 
http://links.lww.com/MPG/B773, which demonstrates the study population and 
design). The hospital patient records were reviewed for demographics, 
underlying diagnoses, medications, laboratory test and liver biopsy results, 
imaging results, endoscopic and surgical procedures, complications, variceal 
bleeding episodes, and survival. All patients were followed up through the 
Finnish National Care Register for Health Care (National Institute for Health and 






gister_healthcare#data) from 1972 to 2013 to assure complete data capture. The 
register maintains nationwide data of diagnosis and treatments in Finnish 
hospitals. A systematic search was performed by linking personal identity codes 
to the International Classification of Diseases codes (ICD-8, ICD-9 and ICD-10) 
and the Nordic Classification of Surgical Procedures (NCSP) or the Finnish 
Classification of Surgical Procedures (before introduction of NCSP in 1997). 
Causes of death were verified from the nationwide Archive of Death Certificates 
of Statistics Finland (http://www.stat.fi/tup/kuolintodistusarkisto/index_en.html). A 
structured questionnaire was sent to all survivors to gather data on current 
follow-up, treatment, symptoms and health perceptions (See Supplemental 
Digital Content 2, http://links.lww.com/MPG/B774, which includes the structured 
questionnaire). 
We defined hypersplenism as blood platelet count consistently less than 150 
E9/L, and splenomegaly as spleen length measured in abdominal ultrasound 
examination above 1 SD of age-specific reference value (33).  
 
Management of portal hypertension and esophageal varices 
The Helsinki University Children’s Hospital is the nationwide tertiary referral 
center for pediatric liver diseases in Finland and established national pediatric LT 
program in 1987. Since then Finnish BA patients and other children with 
significant liver diseases have been followed-up in Helsinki, where they undergo 
yearly endoscopic variceal surveillance combined with abdominal ultrasound 
examination and blood tests (34,35). In BA, the endoscopic surveillance was 




started at 12 months, or earlier, if clinical signs of advanced PH or bleeding 
occurred. In other patients, endoscopies were commenced once the diagnosis 
was established. 
 Upper gastrointestinal endoscopies were performed under general 
anesthesia by an experienced endoscopist. Number and grade of esophageal 
varices were recorded according to Cales classification (36). Other location of 
varices and the presence of portal hypertensive gastropathy was also recorded. 
When encountered, grade 2 and 3 esophageal varices were treated with 
prophylactic injection sclerotherapy using sodium tetradecyl sulfate (Fibrovein, 
Std Pharmaceutical Product Ltd, Hereford, UK, or Sotradecol, AngioDynamics, 
New York). Sclerotherapies were repeated at 2- to 4-week intervals until varices 
were considered eradicated. Surveillance endoscopies were usually repeated at 
yearly intervals. Instead of injection sclerotherapy, band ligations were 
increasingly performed beyond infancy towards the end of inclusion period. If 
acute variceal bleeding was not successfully controlled endoscopically, 
Sengstaken-Blakemore tube was introduced with or without octreotide therapy. 
Propranolol was used as a secondary prophylaxis in selected high-risk patients 
or in those with recurrent variceal bleeding episodes despite endoscopic 
sclerotherapy. 
 Surgical treatment of biliary atresia was nationally centralized to Helsinki 
in 2005 (16). Pediatric portosystemic shunt surgery is also centralized to 
Helsinki, where mesoportal bypass operations were started in 2002 (19). 
Mesoportal bypass (Rex shunt) is offered to all EHPVO patients with favorable 
anatomy, while other shunts are performed individually based on symptoms, liver 
function and underlying liver disease. 






The study conforms to the principles of the 1975 Declaration of Helsinki and was 
approved by the hospital ethical committee and the National Institute for Health and 
Welfare. All patients participated in the study on a voluntary basis. An informed 
written consent was received from all participating patients and/or their parents. 
 
Statistical analyses 
Data are presented as median and range. Continuous independent variables were 
compared with Mann Whitney U test. Comparisons between categorical variables 
were performed with the chi-square test. Correlations were analyzed with Spearman 
rank correlation test. Cumulative risks were assessed with the Kaplan-Meier method. 
SPSS version 25.0 (IBM SPSS Statistics, Armonk, NY) was used for statistical 
analyses. For analytic purposes, patients were divided into three groups (BA, 
EHPVO and others) based on the underlying etiology. Level of statistical significance 




In total, 126 patients with median follow-up of 15.2 (0.5-43) years were included. 
Patient characteristics are summarized in Table 1. The level of PH was classified as 
intrahepatic in 63%, prehepatic in 36% and posthepatic in only one case (0.8%). As 
expected, of the 19 different underlying conditions, BA (35%) and EHPVO (35%) 
were the most common ones. Fifty-seven (45%) patients had associated disorders, 
including respiratory diseases (n=9), neurologic conditions (n=8), congenital cardiac 




defects (n=7), extra-hepatic malignancies (n=4), inflammatory bowel disease (n=4), 
Down syndrome (n=2), Sotos syndrome (n=1), and an unidentified metabolic 
syndrome (n=1). Four patients (9% of BA patients) had splenic malformations related 
to BA, including polysplenia (n=3), and asplenia (n=1). Forty-two (95%) BA patients 
had undergone Kasai portoenterostomy procedure to relieve cholestasis. 
 
Gastroesophageal varices and endoscopic management 
Patients underwent median 9 (1-74) upper gastrointestinal endoscopies during 
the follow-up. The first endoscopy was performed at age of 4.8 (0.2-17.0) years. 
Endoscopic findings are summarized in Table 2. Gastric varices were 
encountered in 19 (15%) patients, always in conjunction with esophageal varices 
in the fundus (n=11), antrum (n=3), corpus (n=2), duodenum (n=1) or multiple 
locations (n=3). Hypertensive gastropathy was observed in 69 (55%) patients 
with comparable frequency in different groups, although earlier in BA patients. 
Esophageal varices were observed and they bled earlier in BA patients than in 
others (Table 2 and Fig. 1). Overall, median of 6 (1-56) sclerotherapies or band 
ligations (6 patients in 11 sessions) were performed to 112 (89%) patients.  
 
Surgical procedures to alleviate portal hypertension 
Including LT, 88 (70%) individual patients underwent surgery to alleviate PH. 
Forty-eight (38%) patients underwent LT at median age 5.5 (0.4-29.2) years. 
Forty-eight surgical shunt procedures were performed to 41 (36%) patients, 
including mesoportal bypass (n=27), mesocaval shunt (n=7), side-to-side 
splenorenal shunt (n=6), distal (Warren) splenorenal shunt n=4, proximal 
splenorenal shunt (n=2) and other shunts (n=2). Median age at first shunt 




procedure was 8.0 (0.4-13.7) years. Of the patients who underwent shunt 
surgery, 88% (n=36) had EHPVO, while none of EHPVO patients were 
transplanted. Two BA patients with a mesocaval shunt and one ARPKD patient 
with a side-to-side splenorenal shunt required subsequently LT due to liver 
failure or hepatic encephalopathy. Cumulative patency rates for surgical shunts 
are shown in Figure 1. Patency rates for different shunt types were as follows: 
mesoportal bypass 74% (20/27), side-to-side splenorenal shunt 83% (5/6), 
Warren shunt 100% (4/4), proximal splenorenal shunt 50% (1/2), mesocaval 
shunt 29% (2/7), and other shunt 50% (1/2). Overall, 84% (32/38) of surviving 
patients had a functioning shunt at the end of follow-up. 
 
Variceal bleeding 
Overall, 61 (48%) patients experienced median of 2 (range 1-20) variceal 
bleeding episodes. Thirty-seven (61%) patients bled also after commencing 
endoscopic sclerotherapy and 8 patients after shunt surgery (See Supplemental 
Figure 2, Supplemental Digital Content 1, http://links.lww.com/MPG/B773, which 
demonstrates the cumulative survival without variceal bleeding after first surgical 
shunt procedure and first endoscopic sclerotherapy session). Nine patients 
experienced variceal bleeding at some point after the first LT (n=4; 8.5%) or 
shunt surgery (n=5; 12%). Median number of bleeding episodes/patient was 
comparable in different groups. Ectopic varices bled in 6 (30% of patients with 
ectopic varices) patients. Variceal bleeding necessitated balloon tamponade in 8 
(13% of patients with variceal bleeding) cases, and an emergency shunt 
procedure (mesocaval shunt) in one BA patient due massive bleeding after band 
ligation of cardiac varices. Betablockers were used in 24 (19%) patients to 




prevent recurrent variceal bleeding. Overall, cumulative survival without variceal 
bleeding at age of 5, 10, 15, and 20 years, was 78%, 61%, 47%, and 39%, 
respectively. As shown in Fig. 2, cumulative risk of variceal bleeding was 
comparable among the three groups (p=0.116). 
 
Splenomegaly, hypersplenism and splenic complications 
Splenomegaly and hypersplenism occurred in 93% and 81% of patients, 
respectively. Maximal spleen length varied from 7 cm to 25 cm. Splenomegaly 
was equally common but developed earlier in BA patients than in others (Table 
2). Hypersplenism was less common in BA patients, although it was detected 
earlier when compared to others. Thirty-six (29%) patients experienced severe 
thrombocytopenia (<50E9/L). Three patients suffered from additional splenic 
complications. One un-operated EHPVO patient experienced a spontaneous 
splenic rupture at 19 years of age requiring splenectomy. Two patients with BA 
and familial cirrhosis bled from a splenic artery aneurysm requiring endovascular 
coiling and splenectomy. No symptomatic splenic infarcts were reported. Overall, 
12 (10%) patients underwent a splenectomy at a median age of 10.2 (range 2.0-
26.5) years. Following LT, mesoportal bypass or other shunt surgery complete 
reversal of splenomegaly (<1 SD) was achieved in 65%, 75%, and 50%, and 
blood platelet count normalized in 47%, 60%, and 46% of patients, respectively. 
The increase in blood platelet count correlated with follow-up time (r=0.322, 
p=0.005). 
 
Other complications of portal hypertension 




Symptomatic portal hypertensive biliopathy was observed in 4 patients with 
EHPVO at median age of 22.9 (13.6-24.8) years. Magnetic resonance 
cholangiopancreatography showed abnormal biliary tract dilatation in every case. 
Two patients suffered cholangitis and one required endoscopic biliary dilatation 
and stenting due a choledochal stricture. Two BA patients developed 
hepatopulmonary syndrome and required LT at the age of 0.6 and 6.5 years. 
One BA patient listed for LT died due to hepatorenal syndrome after cholangitis 
at the age of 5 months. Hepatic encephalopathy was reported in two patients. 
The patient with BA had undergone mesocaval shunt at 5 months age and 
developed liver failure and progressive hepatic encephalopathy requiring LT at 
the age of 15 years. The patient with ARPKD had undergone a side-to-side 
splenorenal shunt at 10 years age and suffered repeated episodes of 
hyperammonemia in addition to progression of liver manifestations (fibrosis, 
cystic biliary dilatation) and kidney graft failure requiring combine liver kidney 




Overall survival was 75% and median age at death 9.4 (0.5-29.4) years. None of 
the deaths were related to variceal bleeding, while all EHPVO patients survived. 
The causes of death were BA (n=16), cystic fibrosis (n=3), undefined liver failure 
(n=3), ARPKD (n=2), non-Hodgkin lymphoma (n=2), Alagille syndrome (n=2), 
alpha-1 antitrypsin deficiency (n=1), hepatocellular carcinoma (n=1), IFALD 
(n=1), and trauma (n=1). Twenty-one (66%) of succumbed patients had 
undergone LT. Statistically significant difference in survival between different 




time periods was no seen. Survival of patients born between 1970 and 2004, and 
between 2005 and 2011 was 73% and 80%, respectively (p=0.483). Survival of 
patients born between 1970 and 1990, and between 1991 and 2000, and 
between 2001 and 2011 was 63%, 83%, and 78%, respectively (p=0.089).    
 
Patient reported outcomes  
Sixty-five (69%) patients answered the questionnaire at a median age of 17.0 
(4.8-43.3) years. The responders (n=65) and non-responders (n=29) were 
comparable regarding sex (male 48% vs 41%, p=0.57), frequency of underlying 
liver disease (BA n=18 vs n=10; EHPVO n=34 vs n=10; other n=13 vs n=9; 
p=0.26), and follow-up age (17.4 (4.3-43.1) years vs 15.2 (2.9-41.4) years, 
p=0.45). Median body mass index of respondents was 20.6 (12.6-31.2) kg/m2. Of 
them, 57% (n=37) were under active surveillance for esophageal varices, 
eighteen (28%) currently used of betablockers, and five (8%) had been 
hospitalized for variceal bleeding during the preceding year. Although 86% 
reported no current symptoms related to varices, 58% and 9% experienced 
abdominal pain occasionally or weekly. Perception of general health on numeric 
scale (1-10) was 9 (4-10). Of the adult respondents (>18 years of age, n=31) 
48% (n=15) were under active follow-up for esophageal varices, and 6% (n=2) 
had been hospitalized for variceal bleeding during the preceding year. 
 
DISCUSSION 
Underlying diseases in pediatric-onset PH are numerous. As in previous studies, 
BA and EHPVO were the most common conditions, comprising 70% of the 
patients in the study population (9,12,13,37). Congenital hepatic fibrosis was 




mainly associated with ARPKD (90%) (9,38), while other underlying diseases 
were infrequent and classified as intrahepatic. Although certain characteristics of 
esophageal varices, surgical management and survival were dependent on the 
underlying disease, the cumulative risk of variceal bleeding was comparable in 
different underlying disease groups. None of our patients died due to variceal 
bleeding, while the estimated mortality rate of variceal hemorrhage in children 
with chronic liver disease is 1-3% (2). In the largest series up to date by Duché 
and coworkers (12), high-risk varices caused life-threatening complications in 1/5 
of children with cirrhosis who bled spontaneously and 2 (2%) patients with non-
cirrhotic PH died due to refractory bleeding. In BA complications of PH develop in 
an early phase (12), and according to our experience high mortality was related 
to other complications of advanced liver disease and its treatment rather than 
variceal bleeding. 
 Recently, management of children with PH has evolved significantly. In 
Finland, BA treatment has been centralized in 2005 to Helsinki resulting in 
increased 5-year native liver survival (from 38% to 70%) and 5-year overall 
survival (from 68% to 94%) (14). Mesoportal bypass has helped to eliminate 
long-term consequences and morbidity of EHPVO in patients with well-preserved 
intrahepatic portal veins (18,20,22,39). Routine preoperative imaging with 
retrograde portography may enhance correct identification of these individuals 
and thereby improve long-term Rex shunt patency rates (40,41). As previous 
studies suggest, Warren shunt and a side-to-side splenorenal shunt seem to be 
rational options with satisfactory long-term patency and symptom relief, if 
mesoportal bypass is not feasible (1,9,18,42). According to our limited experience 
other portosystemic shunts exhibited a relatively high tendency for thrombosis in 




the long-term. Following shunt surgery recurrence of variceal bleeding was 
exclusively related to shunt occlusion or stenosis.  
 Ideal evidence-based treatment algorithms regarding primary and 
secondary prophylaxis of variceal hemorrhage in children are lacking 
(2,10,22,26,28,43). Our long-term results may support endoscopic primary 
prophylaxis (12,25,27) in prevention of variceal bleeding related mortality. 
However, prophylactic endoscopic treatment was combined with surgical 
procedures in a significant proportion of patients, reflecting results our 
multimodal interdisciplinary approach. Hypersplenism is rarely a major issue in 
children and does not cause clinical concern in most cases (1). Severe 
hypersplenism was the main indication for surgery (n=4) or splenic embolization 
(n=1) in only 5% of patients with hypersplenism. Despite successful shunt 
surgery, hypersplenism persist in some patients for incompletely understood 
reasons. It seems that in some patients splenomegaly is irreversible and splenic 
sequestration of blood elements continues despite decreased portal pressure 
(44-47).  
 Limited literature is available on long-term health of patients with pediatric-
onset PH. Health-related quality of life is similar between BA patients and 
matched general population controls (48,49). EHPVO patients seem to have 
reduced quality of life despite variceal eradication mainly due to massive 
splenomegaly and growth retardation (50). Some improvement of QOL scores is 
seen after surgery on a short-term follow-up (50). Despite significant long-term 
morbidity, health perception of our patients was good and majority reported no 
abdominal pain or other symptoms attributable to PH or esophageal varices. At 
median age of 17 years majority of the patients were under endoscopic 




surveillance and 8% had recently required treatment for variceal bleeding. These 
results combined with the other observed complications of PH highlight the 
importance of continuing follow-up in adult expert service. 
 The study population is relatively large representing nearly all patients 
with complicated pediatric-onset PH in Finland since 1987. None of the patients 
were lost to follow-up. Overall, 69% of the survivors answered the questionnaire, 
which is a clear limitation of the study. However, responders and non-responders 
were comparable making generalization of the results more reliable. Another 
limitation of the present study was the significant evolvement of diagnostic and 
management protocols during the study period, including non-invasive detection 
of PH and esophageal varices. In addition, the retrospective study design 
unavoidably leads to some inaccuracies in data collection. Despite these 
limitations, these data provide useful and novel information on long-term 
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Figure 1. Cumulative shunt patency (Kaplan-Meier curve) for different shunt types. 
Uniform line presents mesoportal bypasses (n=27). Dotted line presents all types 
(Warren, side-to-side, proximal) of splenorenal shunts (n=12). Dash line presents 









Figure 2. Cumulative survival (Kaplan-Meier curve) without variceal bleeding in three 
groups based on underlying etiology of portal hypertension. Uniform line presents 
patients with biliary atresia (BA, n=44). Dotted line presents patients with 
extrahepatic portal vein obstruction (EHPVO, n=44). Dash line presents patients with 
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Table 1. Patient characteristics (n=126) 
Characteristic n (%) 
Male 57 (45) 
Underlying liver disease 
     BA 44 (35) 
     EHPVO 44 (35) 
     ARPKD 9 (7) 
     Autoimmune hepatitis 3 (2.4) 
     Cystic fibrosis 3 (2.4) 
     Alagille syndrome 2 (1.6) 
     Alpha-1 antitrypsin deficiency 2 (1.6) 
     Familial cirrhosis 2 (1.6) 
     Tyrosinemia 2 (1.6) 
     IFALD 2 (1.6) 
     Primary sclerosing cholangitis 2 (1.6) 
     Wilson's disease 2 (1.6) 
     AV malformation 1 (0.8) 
     Budd-Chiari syndrome 1 (0.8) 
     Hepatoblastoma 1 (0.8) 
     Hepatocellular carsinoma 1 (0.8) 
     Biliary hypoplasia 1 (0.8) 
     Isolated CHF 1 (0.8) 
     Hepatopatia (unknown) 3 (2.4) 
Sclerotherapy 112 (89) 
Variceal bleeding 61 (48) 
Splenomegaly 117 (93) 
Hypersplenism 102 (81) 
Surgery for portal hypertension 
     Liver transplantation 48 (38) 
     Mesoportal bypass 27 (21) 
     Splenorenal shunt 12 (10) 
     Mesocaval shunt 7 (6) 
     Splenectomy 12 (10) 
Deaths 32 (25) 
BA=biliary atresia; EHPVO=extrahepatic portal vein 
obstruction; IFALD=intestinal failure-associated liver 
disease; CHF=congenital hepatic fibrosis  
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Table 2. Characteristics and comparison of different underlying disease groups 
 
Characteristic All (n=126) BA (n=44) 
EHPVO 
(n=44) Other (n=38) 
p-
value 
Age at follow-up, y * 15.2 (0.5-43.1) 7.9 (0.5-34.6) 18.4 (3.4-43.1) 19.8 (1.4-33.3) 0.001 
Male, n  57 (45%) 15 (34%) 25 (57%) 17 (45%) 0.101 
Age at diagnosis, y * 0.7 (0-17.3) 0.2 (0.1-1.0) 5.0 (0-13.2) 0.8 (0-17.3) 0.001 
Esophageal varices diagnosed, y * 4.0 (0.3-18.2) 1.1 (0.3-8.7) 5.5 (0.3-13.2) 9.2 (0.8-18.2) 0.001 
Gastric varices, n 20 (16%) 4 (9%) 7 (16%) 9 (24%) 0.161 
  Age at diagnosis, y * 10.1 (1.1-17.5) 7.0 (1.1-11.6) 9.3 (5.2-12.4) 12.4 (3.6-17.5) 0.144 
Hypertensive gastropathy, n 69 (55%) 26 (59%) 24 (54%) 19 (32%) 0.734 
   Age at diagnosis, y * 8.1 (0.4-28.0) 1.9 (0.4-13.0) 9.2 (1.2-16.9) 11.5 (1.2-28.0) 0.001 
Variceal bleeding, n 61 (48%) 18 (41%) 26 (59%) 17 (45%) 0.229 
   Age at first bleed, y * 5.5 (0.4-19.7) 1.5 (0.5-15.2) 5.0 (0.4-12.7) 12.4 (1.1-19.7) 0.001 
Sclerotherapy/ligation, n 112 (89%) 40 (91%) 40 (91%) 32 (84%) 0.607 
   Number of sessions, n 6 (1-56) 4 (1-56) 7 (2-29) 7 (1-42) 0.060 
   Age at first session, y * 4.6 (0.3-18.2) 1.2 (0.4-8.7) 6.3 (0.3-11.2) 9.5 (1.2-18.2) 0.001 
Splenomegaly, n 117 (93%) 38 (86%) 42 (95%) 37 (97%) 0.630 
   Age at diagnosis, y * 2.5 (0.01-17.1) 0.5 (0.01-4.1) 4.2 (0.3-13.2) 5.3 (0.1-17.1) 0.001 
Hypersplenism, n 102 (81%) 29 (66%) 39 (88%) 34 (89%) 0.011 
   Age at diagnosis, y * 3.8 (0.01-17.1) 1.4 (0.01-8.0) 4.5 (1.2-13.2) 9.5 (0.2-17.1) 0.001 
Died, n 32 (25%) 16 (36%) 0 16 (42%) 0.001 
* Median (range)           
 
